SXI Life Sciences
7.772,36
PKT
-3,32
PKT
-0,04
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Leider sind zu diesem Wert keine aktuellen Kursdaten verfügbar, die Stammdaten finden Sie im unteren Seitenbereich.
Analysen zu SXI Life Sciences-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 19.03.19 | Roche overweight | Barclays Capital | |
| 14.03.19 | Roche buy | Jefferies & Company Inc. | |
| 04.03.19 | Novartis Neutral | UBS AG | |
| 04.03.19 | Roche Neutral | UBS AG | |
| 26.02.19 | Roche Hold | Deutsche Bank AG | |
| 26.02.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 25.02.19 | Roche Neutral | Credit Suisse Group | |
| 25.02.19 | Roche overweight | Barclays Capital | |
| 25.02.19 | Roche overweight | JP Morgan Chase & Co. | |
| 25.02.19 | Roche buy | Goldman Sachs Group Inc. | |
| 25.02.19 | Roche buy | Jefferies & Company Inc. | |
| 25.02.19 | Roche Neutral | UBS AG | |
| 13.02.19 | Roche Neutral | UBS AG | |
| 11.02.19 | Roche overweight | Morgan Stanley | |
| 06.02.19 | Novartis Hold | HSBC | |
| 04.02.19 | Roche buy | Jefferies & Company Inc. | |
| 04.02.19 | Roche Reduce | HSBC | |
| 04.02.19 | Novartis Hold | Deutsche Bank AG | |
| 01.02.19 | Roche Reduce | HSBC | |
| 01.02.19 | Novartis Underweight | Barclays Capital | |
| 01.02.19 | Roche Neutral | Credit Suisse Group | |
| 01.02.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 31.01.19 | Roche Neutral | UBS AG | |
| 31.01.19 | Roche Hold | Deutsche Bank AG | |
| 31.01.19 | Novartis Neutral | Credit Suisse Group | |
| 31.01.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 31.01.19 | Roche overweight | JP Morgan Chase & Co. | |
| 31.01.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 31.01.19 | Roche buy | Jefferies & Company Inc. | |
| 30.01.19 | Novartis Hold | Deutsche Bank AG | |
| 30.01.19 | Roche buy | Goldman Sachs Group Inc. | |
| 30.01.19 | Novartis Neutral | UBS AG | |
| 30.01.19 | Novartis buy | Kepler Cheuvreux | |
| 30.01.19 | Roche Neutral | UBS AG | |
| 30.01.19 | Novartis buy | Jefferies & Company Inc. | |
| 29.01.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 29.01.19 | Roche overweight | Barclays Capital | |
| 28.01.19 | Roche Neutral | Credit Suisse Group | |
| 24.01.19 | Roche Conviction Buy | Goldman Sachs Group Inc. | |
| 24.01.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. |